The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
The company might finally become an oncology player.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
But the unveiling of sotorasib’s registrational dataset shows that bulls should be cautious of Mirati's numerical advantage.
Mirati’s Kras inhibitor looks better than Amgen’s on efficacy, but toxicity worries prevent a knockout punch.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.